1. Introduction {#sec1-toxins-08-00340}
===============

*Clostridium perfringens* is Gram-positive, rod-shaped, spore-forming, and anaerobic (but not strictly anaerobic) \[[@B1-toxins-08-00340]\]. This commensal bacterium is ubiquitous in the gastrointestinal tract of healthy humans and animals \[[@B1-toxins-08-00340],[@B2-toxins-08-00340],[@B3-toxins-08-00340]\]. To date, it is known that *C. perfringens* produces up to 18 toxins: alpha (CPA), beta (CPB), epsilon (ETX), iota (CPI), enterotoxin (CPE), theta/perfringolysin O (PFO), beta-2 (CPB2), TpeL, NetB, NetF, BecA/B, NanI, NanJ, kappa, mu, lambda, α-clostripain, and delta toxin \[[@B4-toxins-08-00340]\]. CPA, CPB, ETX, and CPI are used to group *C. perfringens* into five toxinotypes (A--E) according to the toxins that the bacterium produces \[[@B5-toxins-08-00340]\]. Each toxinotype causes different diseases in a range of farm animals and humans \[[@B6-toxins-08-00340]\].

There are two main routes by which the *C. perfringens* can infect animals and humans. The iatrogenic or traumatic route is exclusive to *C. perfringens* toxinotype A, and causes gas gangrene or malignant edema. The second route is by ingestion of spores or through changes in the gut flora followed by excessive growth of *C. perfringens* and toxin production, which causes enterotoxemia, necrotic hemorrhagic enteritis, and enterocolitis \[[@B1-toxins-08-00340],[@B6-toxins-08-00340],[@B7-toxins-08-00340],[@B8-toxins-08-00340]\]. This second route of infection is common to all toxinotypes. Diseases caused by CPA, CPB, and ETX are responsible for significant economic losses throughout the world due to their high lethality rates and because they affect farm animals that have a high zootechnical performance ([Table 1](#toxins-08-00340-t001){ref-type="table"}) \[[@B6-toxins-08-00340],[@B9-toxins-08-00340]\]. In Brazil only, clostridiosis are the cause of death of approximately 500,000 bovines per year, resulting in a loss of about US\$350 million \[[@B10-toxins-08-00340]\].

*C. perfringens* infections can be treated through the administration of penicillin G, hyperbaric oxygen, and monoclonal antibodies, or through the surgical removal of affected tissues \[[@B12-toxins-08-00340],[@B13-toxins-08-00340],[@B14-toxins-08-00340],[@B15-toxins-08-00340]\]. Although not completely effective in humans, these treatments are an alternative. However, for farm animals, these options are usually not viable, since death occurs very quickly \[[@B12-toxins-08-00340]\]. Therefore, prophylactic measures need to be employed to fight *C. perfringens* infections. Vaccination against CPA, CPB, and ETX currently represents the best prophylactic measure. Toxoids are obtained from growing *C. perfringens* and inactivating the toxins using formaldehyde \[[@B16-toxins-08-00340],[@B17-toxins-08-00340]\]. Even though toxoids induce the production of neutralizing antibodies, they present some drawbacks. For example, they are associated with a risk of residual toxicity due to incomplete formaldehyde inactivation and a risk of residual formaldehyde being present \[[@B18-toxins-08-00340],[@B19-toxins-08-00340],[@B20-toxins-08-00340]\]. Furthermore, the potency of the vaccine varies from batch to batch \[[@B17-toxins-08-00340],[@B21-toxins-08-00340],[@B22-toxins-08-00340]\]. In addition, the toxoids that are produced from the supernatant of *C. perfringens* cultures are not pure (i.e., other toxins and proteins are present), and this accounts for a higher degree of antigen diversity in the vaccine \[[@B23-toxins-08-00340]\]. Finally, growing *C. perfringens* poses a significant biosafety risk and requires the application of strict biosafety measures.

More than 150 million clostridial toxoid doses are produced annually in Brazil \[[@B22-toxins-08-00340]\]. The rate of production of the clostridial vaccine is increasing on an annual basis as the number of farm animals continually rises. At present, it is impossible to eradicate *C. perfringens*. Recombinant versions of CPA, CPB, and ETX, which are produced mainly in *Escherichia coli*, have gained ground as promising alternatives to the clostridial vaccine because they present solutions for the aforementioned issues. The use of non-pathogenic *E. coli* strains and the fact that recombinant toxins may present reduced or no toxicity can minimize, or even obliterate, some of the problems associated with native toxin production. Furthermore, heterologous protein expression in *E. coli* can be tightly controlled, allowing the uniform production of recombinant toxins once the culture conditions have been optimized. Because some recombinant toxins have barely any toxicity, there is no requirement for the use of formaldehyde, which makes the production process simpler and safer. Finally, yet importantly, growing *E. coli* is a less laborious process than cultivating *C. perfringens*.

Recombinant proteins in *E. coli* are expressed in different amounts either as: (1) a soluble protein; (2) an insoluble protein; or (3) a mix of both forms depending on the protein itself. *E. coli* expression strain, expression vector, coding DNA and protein sequences, growth conditions (e.g., temperature, medium, etc.), and inductor concentration can influence the amount and solubility of the recombinant protein \[[@B24-toxins-08-00340],[@B25-toxins-08-00340]\]. Both soluble and insoluble forms of recombinant proteins present pros and cons from the perspective of vaccine production. It is highly likely that the soluble recombinant proteins present the same 3D conformation as the native protein, maintaining the conformational epitopes that might be crucial to confer immunity. A further advantage of soluble recombinant proteins obtained in the cell lysate supernatant (CLS) is that they do not require denaturing for purification, requiring only the removal of other proteins and LPS, which can be performed by a combination of different chromatography techniques (e.g., affinity, ion exchange, size exclusion, etc.). Insoluble proteins, on the other hand, may achieve higher levels of purity as inclusion bodies can be washed several times. Furthermore, different chromatography techniques can also be employed for insoluble proteins provided they go through denaturation and refolding steps. However, insoluble proteins may lack conformational epitopes that are crucial for immunity, and refolding steps do not guarantee that these epitopes recovered on the protein structure.

In recent years, researchers have invested significant energy in developing more industry-friendly methods of producing recombinant proteins. Non-purified inclusion bodies and CLS have been tested as immunogens against *C. perfringens* toxins in both experimental and farm animals \[[@B20-toxins-08-00340],[@B22-toxins-08-00340],[@B26-toxins-08-00340]\]. Moreira Jr et al. \[[@B27-toxins-08-00340]\] immunized guinea pigs with inclusion bodies and CLS, and they also validated this strategy against botulinum toxins serotypes C and D. Their results enhanced the appeal of non-purified recombinant proteins for use in veterinary vaccine industries. The aim of the current review was to examine the most frequently used strategies to produce recombinant CPA, CPB, and ETX toxins. Additionally, this review accesses the protective potential of the recombinant toxins produced under different conditions for mammalian livestock animals.

2. Alpha Toxin (CPA) {#sec2-toxins-08-00340}
====================

CPA is coded by the chromosomic gene *plc*. This gene is present in every toxinotype and is expressed at the highest levels in toxinotype A \[[@B28-toxins-08-00340]\]. The active toxin CPA is a 370-residue long, zinc-dependent, phospholipase C (PLC) with sphingomyelinase and lectinase activity and approximately 42.528 kDa \[[@B29-toxins-08-00340],[@B30-toxins-08-00340]\]. The LD~50~ for CPA has been calculated as 3 µg/kg in mice \[[@B11-toxins-08-00340]\]. This toxin is divided into the *N*-terminal (1--246) and the *C*-terminal (247--370) domains. The *N*-terminal domain comprises the catalytic core of the toxin, while the *C*-terminal domain and the central loop (55--93) are responsible for binding host phospholipids and GM1a ganglioside respectively (for review, see Oda et al. \[[@B31-toxins-08-00340]\]). Two zinc ions (Zn^2+^) are strongly bound to CPA. One ion is bound to His148 and Glu152 and is crucial for enzymatic activity. The remaining ion is bound to His11 and Asp130 and has structural function \[[@B32-toxins-08-00340],[@B33-toxins-08-00340]\]. Histidine residues 68, 126, and 136 also bind calcium and help the toxin bind phospholipids in the host cell membrane.

CPA is responsible for intravascular hemolysis, platelet aggregation, and capillary damage. These factors stop leukocytes and oxygen from getting to the site of infection and create an environment that is favorable for the proliferation of *C. perfringens*. In gas gangrene cases, CPA helps immune evasion by interfering in neutrophil migration to the infected tissue, minimizing the number of mature cells in the bone marrow, and causing the accumulation of neutrophils in adjacent vessels \[[@B34-toxins-08-00340]\].

Recombinant CPA Production Strategies and Animal Model Immunizations
--------------------------------------------------------------------

The first studies involving the cloning and expression of the gene encoding CPA determined the nucleotide sequence and protein molecular weight of CPA \[[@B35-toxins-08-00340],[@B36-toxins-08-00340],[@B37-toxins-08-00340],[@B38-toxins-08-00340],[@B39-toxins-08-00340]\]. This way, a 28-amino acid *N*-terminal signal peptide was identified, as well as some biochemical properties of the toxin were described. Many strategies have been employed in an attempt to obtain a non-toxic version of CPA for vaccination, the most common of which are site-directed mutagenesis, isolation of the strains that naturally produce non-toxic CPA, expression of only the *N*- or *C*-terminal domain, expression of chimeric toxins, and expression on the surface of *Bacillus subtilis* spores ([Table 2](#toxins-08-00340-t002){ref-type="table"}) \[[@B32-toxins-08-00340],[@B40-toxins-08-00340],[@B41-toxins-08-00340],[@B42-toxins-08-00340],[@B43-toxins-08-00340],[@B44-toxins-08-00340],[@B45-toxins-08-00340]\].

Site-directed mutagenesis studies initially aimed to characterize essential residues for CPA toxicity and became the base for the production of genetically modified, non-toxic, immunogenic, recombinant CPA. It has been reported that the H68G, H148G/L, D56G, and E152Q mutations are capable of obliterating the toxicity of CPA \[[@B32-toxins-08-00340],[@B33-toxins-08-00340]\]. In one study, mutation of D56N was able to reduce platelet aggregation and PLC activity, thereby increasing LD~50~ from 0.5 to 100 μg/kg in mice \[[@B49-toxins-08-00340]\]. The researchers found that the mutation T272P reduced CPA toxicity by 35% \[[@B50-toxins-08-00340]\]. Site-directed mutagenesis of D336N, Y275N, D269N, Y331L, Y331F, Y307F, and Y275F reduced hemolytic activity by 11%, 11%, 19%, 30%, 36%, 38%, and 73%, respectively \[[@B51-toxins-08-00340]\]. Shoepe et al. \[[@B45-toxins-08-00340]\] identified a naturally occurring non-toxic variant of CPA (CPA-121A/91) with M13V, A174N, T177A, H212R, P295Q, S335P, I345V, and W360G mutations. This variant presented no hemolytic, PLC, or sphingomyelinase activity. In an alternative study, vaccinations with CPA-121A/91 were able to extend the lifespan of challenged mice, but could not prevent death. Interestingly, reversion of the H212R mutation was able to protect 76% (17/21) of the vaccinated mice \[[@B52-toxins-08-00340]\]. These results provide some insights into the possible epitopes and crucial sites for the toxin to act, and might prove useful for the development of both protective and therapeutic antibodies.

Recombinant, non-mutated CPA may present residual toxicity with dermonecrotic activity and might not be suitable for vaccination \[[@B53-toxins-08-00340]\]. Formaldehyde is extensively used to detoxify native CPA, although it also reduces immunogenicity \[[@B19-toxins-08-00340],[@B54-toxins-08-00340],[@B55-toxins-08-00340]\]. Alternatively, site-direct mutagenized recombinant or naturally occurring non-toxic CPA could be used for vaccination; however, in such cases, the immune response will be against the whole toxin, not solely the protective epitopes. Immunization of mice with *N*- and *C*-terminal domains of CPA (CPA-N^(1--246)^ and CPA-C^(247--370)^, respectively), or with the latter fused to GST (GST-CPA-C^(247--370)^) expressed in *E. coli* demonstrated that CPA-C^(247--370)^ (19 kDa) alone is capable of conferring immunity against challenge with 50 µg of CPA or 10^9^ *C. perfringens* cells \[[@B44-toxins-08-00340],[@B48-toxins-08-00340]\]. Animals inoculated with CPA-N^(1−246)^ were not protected against CPA. Taken together, these results indicate that blocking CPA binding to host cell is a necessary and sufficient method of conferring immunity against this toxin. It negates the need to neutralize its enzymatic activity and renders the *C*-terminal domain as the main vaccine candidate against CPA. Furthermore, in one study, mice vaccinated with rCPA-C^(247--370)^ were protected against PLCs from *Clostridium absonum* (CAA) and *Clostridium bifermentans* (Cpb), which share 60% and 50% identity respectively with *C. perfringens* CPA \[[@B46-toxins-08-00340]\].

Structural vaccinology is a branch of structural biology that studies the epitopes responsible for conferring immunity. It is possible to design chimeras that consist only of protective epitopes of different toxins and to exclude the domains that do not confer immunity. This approach simplifies the production process because only one process is required to produce a chimera that can confer immunity to a range of toxins as opposed to many processes being executed for different toxins \[[@B56-toxins-08-00340]\]. Considering this, modifying the whole rCPA molecule excluding unnecessary domains would be a useful approach. In fact, the rCPA-C^(247--370)^ domain is being used to replace the whole rCPA as vaccine component, allowing the construction of novel chimeras for experimental vaccines against *C. perfringens*. For example, a recombinant chimera (rCPAE) comprising CPA-C^(284--398)^, fused to the *C*-terminal portion of *C. perfringens* Enterotoxin (CPE-C^(197--312)^), was found to protect 100% (12/12) of mice challenged with CPA, and 75% (9/12) of mice challenged with CPE \[[@B43-toxins-08-00340]\]. The protection induced rCPAE face the challenge with both CPA and CPE toxins has not been evaluated. CPA-C^(284--398)^ fused to the *N*-terminal domain of *Staphylococcus aureus* Alpha-hemolysin (SAA^(36--221)^) protected 100% (6/6) of mice challenged with either CPA or SAA, and 81.3% (5/6) of mice challenged with both toxins ([Figure 1](#toxins-08-00340-f001){ref-type="fig"}) \[[@B41-toxins-08-00340]\].

Zeng et al. \[[@B26-toxins-08-00340]\] evaluated four vaccine formulations against *C. perfringens* toxins: (1) rCPA; (2) bivalent recombinant chimera comprised of CPB and CPB2---rCPB2B1; (3) co-administration of rCPB2B1 and rCPA; and (4) trivalent recombinant chimera comprised CPA, CPB, and CPB2---rCPAB2B1. The recombinant antigens were expressed and used as inclusion bodies in immunizations. Mice vaccinated with rCPA presented 80% protection (24/30) when challenged with 1 × LD~100~ of *C. perfringens* toxinotype C culture supernatant. Group 3 was 100% (30/30) protected against twice the challenge dose of Group 1. Group 4 was 93% (28/30) protected against the same challenge. The authors argued that the lower protection observed in Group 4 in comparison to the groups that received co-administered antigens was due to an alteration in conformational epitopes that resulted from many antigens joining together in only one polypeptide chain. Goossens et al. \[[@B53-toxins-08-00340]\] demonstrated that animals inoculated with GST-CPA-C^(247--370)^ were less protected than animals inoculated with CPA-C^(247--370)^ alone, suggesting that the presence of GST disrupts the protective potential of the *C*-terminal domain of CPA. Williamson and Titball \[[@B44-toxins-08-00340]\] previously obtained similar results when mice vaccinated with CPA-C^(247--370)^ produced two times as many neutralizing antibodies as mice vaccinated with GST-CPA-C^(247--370)^. Surprisingly, the GST-CPA-C^(247--370)^ chimera expressed on the surface of *B. subtilis* spores elicited the production of both systemic IgG and sIgA in the saliva, feces, and lung samples of the vaccinated animals. Mice immunized with 2 × 10^9^ or 5 × 10^10^ orally or intranasally respectively, were 100% (6/6) protected against 12 × LD~50~ \[[@B40-toxins-08-00340]\]. These results suggest that it is not just vaccine composition and antigen design that are essential to the generation of immunity, but also the fashion in which antigens are presented to the immune system is crucial to achieving immunity against high doses of challenge. We strongly suggest all these aspects are taken into account when designing and testing novel vaccines, not only for clostridial toxins but also for all pathogens.

*E. coli* is by far the most used expression system for the expression of rCPA. Two kinds of plasmid vectors are frequently employed for this purpose: pT7, and pET. Both vectors contain the T7 promoter, an antibiotic resistance gene, and a copy of the *lacI* gene for the regulation of the expression. The *E. coli* strain BL21 (DE3), which contains the coding gene for the T7 DNA polymerase in its genome under the control of lac operon, is the most commonly used strain. Lactose or similar molecules, such as alollactose or the synthetic derivate of galactose isopropyl-β-1-[d]{.smallcaps}-galactopiranoside (IPTG), which cannot be metabolically degraded by *E. coli*, can induce the lac operon. For the expression of rCPA, concentrations of 0.3--1 mM of IPTG are described in the literature as successful, and, most interestingly, only one work has described the attainment of an insoluble protein, although the culture conditions (i.e., medium, temperature, and induction time) were very similar to other works that described soluble rCPA. The expression of insoluble antigens is always perceived to be a problem for recombinant vaccine development since many protective epitopes can be lost due to erroneous protein folding. Thus, the optimization of expression conditions (medium, inductor concentration, pre-induction, and induction time, etc.) is often indicated. However, Zeng et al. \[[@B26-toxins-08-00340]\] described how the inclusion bodies of rCPA can be successfully used for animal vaccination without the need for denaturation, refolding, or even purification.

3. Beta Toxin (CPB) {#sec3-toxins-08-00340}
===================

CPB is coded by the plasmid-encoded gene *cpb* and is a member of the heptameric proteins family that is known as beta-pore-forming toxins (BPFT) \[[@B57-toxins-08-00340]\]. Expression of this gene results in a protoxin with 336 amino acids. When it is secreted, a 27-amino acid signal peptide is removed, resulting in the active toxin with 34.861 kDa. This toxin has the ability to form oligomers in vitro, an activity that allows it to develop cation-selective channels of approximately 228 kDa and 12 Å diameter within the lipid microdomains composed of phosphatidylcholine and cholesterol in the plasma membrane \[[@B58-toxins-08-00340]\]. The LD~50~ for CPB in mice is 0.4 µg/kg, and its toxicity is characterized by a fatal necrosis without hemolysis \[[@B11-toxins-08-00340]\]. This toxin is also sensitive to trypsin, which can completely inhibit its activity. As such, newborn animals are at risk of being infected by CPB-mediated disease as they produce low amounts of gastric proteases and colostrum also contains trypsin inhibitors \[[@B6-toxins-08-00340],[@B59-toxins-08-00340]\].

Recombinant CPB Production Strategies and Animal Model Immunizations
--------------------------------------------------------------------

Early studies of the *cpb* gene from *C. perfringens* type B strain NCTC8533 described its identification, sequencing, and cloning into the pBET7 vector for expression on *E. coli* JM109. The protein exhibited approximately 34 kDa and reacted against antibodies raised for the native CPB \[[@B60-toxins-08-00340]\]. Further studies have focused on determining the toxicity mechanism of CPB and have generated important recommendations for vaccinology specialists that have facilitated the development of recombinant vaccines \[[@B61-toxins-08-00340],[@B62-toxins-08-00340],[@B63-toxins-08-00340],[@B64-toxins-08-00340]\]. Of the various strategies that are used to develop recombinant vaccines containing CPB, four approaches, in particular, are worth highlighting: (1) the insertion of point mutations for the generation of toxoids; (2) the expression of the whole toxin sequence; (3) the expression of its *C*-terminal domain (CPB-C^(143--311)^); and (4) the expression of chimeric antigens containing other toxins (e.g., CPA, CPB2, or ETX) or the B subunit of the heat-labile enterotoxin of *E. coli* (LTB) ([Table 3](#toxins-08-00340-t003){ref-type="table"}) \[[@B18-toxins-08-00340],[@B26-toxins-08-00340],[@B65-toxins-08-00340],[@B66-toxins-08-00340],[@B67-toxins-08-00340],[@B68-toxins-08-00340],[@B69-toxins-08-00340],[@B70-toxins-08-00340],[@B71-toxins-08-00340]\].

In terms of the first mentioned approach to generating possible vaccine candidates, it is known that the Y203F, R212E, and R121Q mutations are able to increase the LD~50~ by CPB 2.5, 12.5, and 5.5 times respectively \[[@B65-toxins-08-00340],[@B66-toxins-08-00340]\]. However, Nagahama et al. \[[@B72-toxins-08-00340]\] obtained a non-toxic rCPB molecule by introducing the Y266A, L268G, and W275A mutations in combination, or by substituting C265 for Tyrosine or Histidine. However, none of these constructs were evaluated in terms of their ability to generate protective antibodies when injected into animal models.

One successful study that used the whole toxin sequence was performed by subcloning the coding sequence of CPB into the pAE vector for expression in *E. coli* BL21 (DE3) Star^TM^ \[[@B67-toxins-08-00340]\]. The resulting protein was obtained in inclusion bodies, which had to be suspended with urea. After purification, a refolding step was conducted using PBS, and this resulted in a completely non-toxic protein. In this case, this protein was able to generate 10 IU/mL of protective antibodies when 100 µg of rCPB was injected in rabbits. Although the refolding step is usually considered a problem, it is possible that it plays an important role in reducing or eliminating the toxicity of the protein, as was the case in this study. On the other hand, other options, such as using the inclusion bodies directly (without purification and further refolding) have proven to be successful for rCPA and rETX in terms of both maintaining the non-toxicity of the proteins and generating high levels of protective antibodies \[[@B22-toxins-08-00340],[@B26-toxins-08-00340]\]. If there is a necessity to eliminate the refolding step, the direct use of the rCPB inclusion bodies appears to represent a reasonable approach to doing so.

By analyzing the sequence of CPB, it was determined that its *C*-terminus residues (CPB^(256--276)^) are closely related to the *C*-terminal part of alpha toxin from *S. aureus* (SAA^(245--267)^) \[[@B72-toxins-08-00340]\]. This supports the finding that CPB^(256--276)^ has a similar function and, therefore, it is responsible for binding to the cell receptor. As is the case with other toxins, such as botulinum neurotoxins, the receptor-binding domain usually contains the major part of the protective epitopes. An in silico study determined three possible B-cell epitopes in CPB (amino acids 32--45, 140--156, and 260--275) \[[@B18-toxins-08-00340]\]. However, although the epitope CPB^(140--156)^ was fused to the LTB molecule for further characterization, none of these epitopes were tested in experimental vaccines, leaving an open space for the investigation of minor regions of the protein that can lead to protective immune responses.

Bearing in mind the fact that epitopes have yet to be tested as vaccine candidates, the use of whole proteins or smaller parts of the protein fused to other antigens is also a strategy that is in need of further exploration ([Figure 2](#toxins-08-00340-f002){ref-type="fig"}). A study with the region CPB^(143--311)^, which was fused to the *C*-terminal part of CPI (CPI-C^(466--665)^), showed that the resulting protein (called rCPIB) was able to protect 83% and 91% of mice challenged with 5 × LD~100~ of CPI and CPB, respectively \[[@B70-toxins-08-00340]\]. Similarly, Bai et al. \[[@B73-toxins-08-00340]\] produced a bivalent chimera that contained CPA and CPB (rCPAB), which was able to protect 100% (10/10) of mice challenged with 1 L+ of CPB. Another chimeric antigen with ETX and CPB (rETXCPB) was able to generate titers of 6 and 10 IU/mL against the respective toxins in rabbits \[[@B71-toxins-08-00340]\]. A similar approach that employed two variants of CPB (chimera rCPB2B1) was able to protect 90% (27/30) of mice challenged with 1 × LD~100~ of culture filtrated of *C. perfringens* toxinotype C \[[@B26-toxins-08-00340]\]. In the same study, the co-injection of rCPA plus rCPB2B1 resulted in the 100% (30/30) protection of the challenged mice. This last result indicates that these three toxins, CPA, CPB, and CPB2, have a synergistic effect on the pathogenesis of toxinotype C.

One relevant aspect to the heterologous expression is that of codon optimization. The majority of the time, the use of optimal codons for *E. coli* expression facilitates the attainment of a higher protein yield; however, there is no guarantee that a soluble protein will be obtained. Sakurai and Nagahama \[[@B59-toxins-08-00340]\], for example, obtained an insoluble rCPB even when using *E. coli* optimal codon. The existing literature describes how it is possible to overcome this problem through the use of a chimeric antigen to improve the solubility of the antigen. As described previously, both the rETXCPB and rCPIB contain CPB, or part of it, in the *C*-terminal region, having soluble proteins at the end \[[@B70-toxins-08-00340],[@B71-toxins-08-00340]\]. However, in the same study, both the rCPAB2B1 and the rCPA that were produced during the research were insoluble \[[@B26-toxins-08-00340]\]. Further studies have found that the strain of the *E. coli* can influence the solubility of the protein. For example, Bakhshi et al. \[[@B74-toxins-08-00340]\] found that the rCPB expressed in BL21 (DE3) was insoluble, while that expressed in Rosetta (DE3) was soluble. Reducing the expression temperature (to between 16 and 28 °C) is a common approach by which researchers try to increase protein solubility. However, the use of this method for the expression of rCPB has not been described in the literature.

4. Epsilon Toxin (ETX) {#sec4-toxins-08-00340}
======================

ETX is coded by the plasmid-encoded gene *etx*, and is the third most potent toxin known from *Clostridium* spp., behind botulinum toxins (BoNTs) and tetanus toxin (TeNT) (for review, see Alves et al. \[[@B75-toxins-08-00340]\]). This toxin is part of the pore-forming aerolysin-β-toxins, and is produced by the B and D toxinotypes. ETX is translated as a 32.98 kDa protoxin that is then activated by trypsin and chymotrypsin proteases. It is also thought that λ-protease from *C. perfringens* itself may also activate ETX in some strains \[[@B76-toxins-08-00340],[@B77-toxins-08-00340],[@B78-toxins-08-00340]\]. An ex vivo study on part of a caprine intestine found that the activation of ETX is more complex than initially believed \[[@B79-toxins-08-00340]\]. The active toxin was known to have about 27 kDa based on SDS-PAGE. However, MS analysis showed products with 27.688, 27.801, and 27.900 kDa with divergences on the residues of the *C*-terminal region. This suggested that carboxypeptidases other than trypsin and chymotrypsin could activate ETX \[[@B79-toxins-08-00340]\]. These findings were very important for further studies on the activity of the toxin, since the LD~50~ of the toxin in mice varies from 50 to 320 ng/kg depending on the protease used for activation. For example, the combination of trypsin and chymotrypsin can result in the maximum activation of the toxin, reaching the LD~50~ with 50 ng \[[@B76-toxins-08-00340],[@B77-toxins-08-00340],[@B78-toxins-08-00340]\].

ETX contains three domains: domain I is responsible for the interaction with the host cell receptor, domain II stabilizes the interaction of the toxin with its receptor and triggers the heptamerization, and domain III is responsible for the interaction between the monomers for the formation of the pore on the membrane \[[@B75-toxins-08-00340]\]. Y29, Y30, Y36, Y196, and F199 from domain I are the main amino acids involved in the interaction with the cell surface \[[@B80-toxins-08-00340],[@B81-toxins-08-00340]\]. A further detail about the activity of the toxin that is of significance is that the mutation Y196E and the presence of the 23-amino acid *C*-terminal peptide act mutually to reduce the toxicity of ETX. This *C*-terminal peptide impairs the binding of the toxin to the cell, while the Y196E mutation eliminates the oligomerization and, thus, the pore formation. Jiang et al. \[[@B82-toxins-08-00340]\] evaluated the role Y71 (domain III) plays in ETX activity, and found that the lack of this amino acid eliminates the toxicity when tested in vitro on MDCK (Madin-Darby canine kidney) cells.

Another study on the interaction of ETX with the plasma membrane of MDCK cells found that the hepatitis A virus cell receptor 1 (HAVCR-1), which is present in detergent-resistant microdomains, is the target of ETX \[[@B77-toxins-08-00340],[@B83-toxins-08-00340]\]. Rumah et al. \[[@B84-toxins-08-00340]\] showed binding of ETX to its target cells and its cytotoxic activity on mammalian cells are dependent on myelin and lymphocyte (MAL) protein. The pores formed by ETX include seven monomers of the toxin and some other proteins from the cell membrane, such as caveolin-1 and -2. The whole complex shows around 700 kDa and allows the Na^+^ and Ca^2+^ ions to go inside the cell, resulting in ATP depletion. Furthermore, ETX also increases the permeability of the mitochondrial membrane, causing a rapid transport of the caspase-independent apoptosis factor AIF to the nucleus \[[@B85-toxins-08-00340],[@B86-toxins-08-00340],[@B87-toxins-08-00340]\]. As such, the toxin causes intestinal necrosis, through which the GAP junctions of the enterocytes are rapidly disrupted, allowing ETX to reach the bloodstream and, consequently, other organs such as kidneys, lungs, liver, and the brain \[[@B88-toxins-08-00340]\].

Recombinant ETX Production Strategies and Animal Model Immunizations
--------------------------------------------------------------------

The first study that assessed the cloning, sequencing, and expression of ETX in *E. coli* served as a base for further studies that sought to determine its structure, toxicity, interaction with host cells, and immunogenicity \[[@B22-toxins-08-00340],[@B82-toxins-08-00340],[@B89-toxins-08-00340],[@B90-toxins-08-00340]\]. The recombinant toxin was used to determine the toxicity mechanism, the main susceptible cell types, preferential organs, and potential hosts \[[@B78-toxins-08-00340],[@B91-toxins-08-00340],[@B92-toxins-08-00340],[@B93-toxins-08-00340]\].

A vast number of studies have focused on ETX due to the fact it is the third most potent toxin know and, therefore, is considered a potential biowarfare threat according to the Centers for Disease Control and Prevention (CDC), USA \[[@B94-toxins-08-00340]\]. Even though it is highly lethal to humans, ETX is more prevalent in cases of enterotoxemia in ovine, caprine, and bovine. This disease also acts rapidly and has a high fatality rate. Since treatment is not a feasible option, this increases the need for a prevention method, mainly via vaccination, that can avoid the loss of animals. The main approaches for the development of a recombinant vaccine against ETX are the use of rETX-carrying mutations to eliminate its toxicity, the use of *Lactobacillus casei to* carry these mutated antigens to its surface, the expression of the protoxin (rPETX), and the use of chimeras that contain multiple antigens ([Table 4](#toxins-08-00340-t004){ref-type="table"}) \[[@B20-toxins-08-00340],[@B22-toxins-08-00340],[@B69-toxins-08-00340],[@B71-toxins-08-00340],[@B80-toxins-08-00340],[@B95-toxins-08-00340],[@B96-toxins-08-00340],[@B97-toxins-08-00340],[@B98-toxins-08-00340]\].

In its structure, ETX has two 35-amino acid parallel strands of β-sheets that cross all its structure, passing through domains I, II, and III \[[@B99-toxins-08-00340]\]. For this reason, the use of only one of the domains as a vaccine candidate, what is the case for both CPA and CPB, is still a challenge. Considering this, the current strategies by which rETX is produced for vaccine applications are focused on the development of a non-toxic molecule that is able to generate protective immunity. Thus, many mutated antigens have been developed and tested as vaccine candidates in animal models.

The data presented in [Table 4](#toxins-08-00340-t004){ref-type="table"} indicates that rETX with H106P mutation (rETX^H106P^) is the best-characterized vaccine candidate for protection against the animal diseases caused by *C. perfringens*. rETX^H106P^ is completely non-toxic and has been validated as a safe vaccine antigen against enterotoxemia \[[@B80-toxins-08-00340],[@B92-toxins-08-00340],[@B95-toxins-08-00340],[@B97-toxins-08-00340]\]. Despite having low or null toxicity, rETX with V56C/F118C, S156E, and Y71A mutations have not been validated as potential vaccine antigens \[[@B82-toxins-08-00340],[@B85-toxins-08-00340],[@B100-toxins-08-00340]\]. Other rETX, with Y196E-C and F199E mutations, have shown low toxicity and were used to vaccinate mice. Mice vaccinated with 15 µg of rETX^Y196E^-C were protected against challenge with 500 × LD~50~, although the toxicity of higher doses in farm animals is yet to be studied ([Figure 3](#toxins-08-00340-f003){ref-type="fig"}) \[[@B96-toxins-08-00340]\].

Recently, Alimolaei et al. \[[@B97-toxins-08-00340]\] produced an *L. casei* that presented an rETX^H106P^ antigen on its surface (LC-pT1NX-rETX^H106P^). Mice vaccinated orally with LC-pT1NX-rETX^H106P^ produced mucosal, humoral, and cellular immune responses, surviving the challenge with 200 × LD~50~ ETX. This strategy is promising and offers distinct advantages over parenteral routes due to the ease with which it can be orally administrated and the fact that it is safe because *L. casei* is not pathogenic. ETX^H106P^ is a well-known non-toxic mutant and, in this case, it also has the benefit of being carried by *L. casei*, an organism that is known to have probiotic effects that facilitate the development of mucosal immunity and other benefits for the immune system \[[@B97-toxins-08-00340]\]. This strategy also proved to be effective in immune prophylaxis against tetanus \[[@B101-toxins-08-00340]\]. Chandran et al. \[[@B94-toxins-08-00340]\] used different amounts of formaldehyde-inactivated rETX per dose (50, 100, 200, 300, and 500 µg), as well as 200 µg of rETX co-administered with attenuated Sheep Pox Virus (SPV). The use of 50 µg and 100 µg per dose, induced antitoxin ETX titers of 3 and 5 IU/mL, respectively. There was no difference in the levels of antibodies generated by doses of 200, 300, and 500 µg, all of which produced approximately 7 IU/mL. This study demonstrated that the combination of recombinant and conventional vaccines is possible.

Similarly to the rETX used by Hunter et al. \[[@B90-toxins-08-00340]\], Souza et al. \[[@B98-toxins-08-00340]\] used rETX as a vaccine antigen and, hence, the protoxin (rPETX) was expressed without the sequence MKKNLVKSL at the *N*-terminal extremity. They transformed *E. coli* BL21 (DE3) strain with pET11a vector, resulting in rPETX in the form of inclusion bodies. Rabbits vaccinated with 50, 100, and 200 µg of formaldehyde-inactivated rPETX showed titers with 10, 30, and 40 IU/mL, respectively. The prime immunization was performed with rPETX associated with Freund's complete adjuvant (FCA) and boosted with Freund\'s incomplete adjuvant (FIA). Moreira et al. \[[@B69-toxins-08-00340]\] synthesized a CDS of ETX without the sequence for the 45 amino acids at the *N*-terminal portion using optimized codons for expression in *E. coli* and obtained a soluble rPETX that was non-toxic for MDCK cells. Rabbits vaccinated with 200 µg of rCPA, rCPB, and rPETX co-administered with Al(OH)~3~ as adjuvant showed titers of 25 IU/mL of antitoxin ETX. The dose of 200 µg of rETX used in the above studies induced different antitoxins titers, which may have been influenced by the various adjuvants used or by the presentation form of rETX (soluble or insoluble). It is important to bare in mind the fact that inclusion bodies also have adjuvant properties.

The rETXCPB chimera was developed, and its immunogenicity in mice was determined in a study by Langroudi, Shansara, and Aghaiypour \[[@B71-toxins-08-00340]\]. This study was unclear as to the concentration of the protein used, and no adjuvant was employed. rETX was expressed in soluble form. Of specific interest was the direct use of CLS of *E. coli* expressing rETXCPB for the immunization of the animals. Even the antigens being used without any adjuvant were efficient in inducing levels of the ETX (6 IU/mL) and CPB (10 IU/mL) antitoxins. Thus, the use of both inclusion bodies and CLS has been proven to represent an alternative to conventional toxoids and purified recombinant antigens.

*E. coli* BL21 (DE3) is the most used system for the expression of rETX, rCPA, and rCPB. The strains of *E. coli* BL21 (DE3) pLysS™, Nova Blue (DE3) pLysS™, and Rosetta™ are the most commonly used, employing the pET22b and pET11a vectors. Chandran et al. \[[@B94-toxins-08-00340]\] and Goswami et al. \[[@B102-toxins-08-00340]\] used *E. coli* M15 and the pQE32 vector. This vector has an ampicillin resistance gene, and the expression of the target gene was under the control of the T5 promoter. The T5 promoter, in contrast to the T7 promoter, does not require co-expression of the bacteriophage RNA polymerase because it is recognized by the *E. coli* RNA polymerase. Using this system, these authors obtained 12 to 20 mg/L of purified rETX. The rETX obtained in *E. coli* M15 and BL21 (DE3) was expressed in the form of inclusion bodies. However, most of the other studies involving the expression of rETX obtained this antigen in a soluble form. Miyata et al. \[[@B103-toxins-08-00340]\] demonstrated that removing the *C*-terminal portion (K274-K296) of ETX affects its solubility, which did not occur with the intact protoxin variants (rPETX) without the *N*-terminal extremity, suggesting that the amino acids present in the *C*-terminal region are essential for maintaining the stability and correct conformation of the ETX, and consequently the solubility.

5. Immunogenicity rCPA, rCPB, and rETX in Farm Animals {#sec5-toxins-08-00340}
======================================================

Numerous studies have described the use of recombinant toxins in illness immunoprophylaxis caused by *C. perfringens* in food animals ([Table 5](#toxins-08-00340-t005){ref-type="table"}) \[[@B22-toxins-08-00340],[@B26-toxins-08-00340],[@B68-toxins-08-00340],[@B69-toxins-08-00340],[@B94-toxins-08-00340],[@B104-toxins-08-00340]\]. Jiang et al. \[[@B105-toxins-08-00340]\] evaluated the treatment of calves using a trivalent vaccine that contained 300 µg of each antigen (rCPA^(247--370)^, rCPB and rETX) emulsified in oil adjuvant ISA 15A VG. They obtained titers of 23.04, 33.7, and 9.43 IU/mL of antitoxin CPA, CPB, and ETX, respectively. However, this result should be interpreted with caution because the levels of antibodies were determined by ELISA, which measures total antibodies (neutralizing and non-neutralizing). On the other hand, Moreira et al. \[[@B69-toxins-08-00340]\] evaluated the use of a trivalent vaccine containing 200 µg of each purified recombinant antigen (rCPA, rCPB, and rETX) adsorbed into adjuvant Al(OH)~3~ in ruminants. The titers of the CPA, CPB, and ETX antitoxins in cattle were 5.19, 13.71, and 12.74 IU/mL, respectively; 4.34, 13.71, and 7.66 IU/mL in sheep; and 4.70, 13.71, and 8.91 IU/mL in goats. Moreover, it should be noted that none of the recombinant antigens were inactivated with formaldehyde.

Despite the high potential of recombinant antigens in the immunoprophylaxis of animal diseases caused by *C. perfringens*, it is important to highlight two negative characteristics: (1) the production process and individual purification of each antigen can mean that this technology is not suitable for use in the veterinary industry; and (2) the fact that these antigens have portions that are not relevant to the generation of protective immune response (neutralizing antibodies). Thus, the development of recombinant chimeras containing two or more antigens has been spotlighted, either in immunoprophylaxis of clostridial, or other diseases \[[@B106-toxins-08-00340],[@B107-toxins-08-00340],[@B108-toxins-08-00340]\]. The work of Zeng et al. \[[@B26-toxins-08-00340]\] evaluated the capacity of two vaccine formulations, rCPA plus rCPB2B1 and a trivalent chimera rCPAB2B1, to generate neutralizing antitoxin in the serum and colostrum of swine and bovine. The individual titers of each antitoxin (CPA, CPB, and CPB2) were determined using culture supernatant of *C. perfringens* toxinotype C for the titration of antitoxin levels. An rCPA plus rCPB2B1 formulation induced titers of antitoxin 3 and 8 IU/mL in serum, and 1 and 6 IU/mL in swine and cow colostrum, respectively. The trivalent chimera rCPAB2B1 induced serum titers of 2 and 6 IU/mL, and 1 and 2 IU/mL in the colostrum of sows and cows respectively. Similarly, as per the studies on mice, the trivalent chimera rCPAB2B1 induced lower titers both in serum and in the colostrum of swine and beef matrices.

The recombinant chimeras in the above-cited studies eliminate the need for production of the individual antigens. However, these chimeras were constructed using intact toxins. Furthermore, the low titers of antitoxin generated by trivalent chimera rCPAB2B1 suggest a possible inappropriate conformation of the molecule, masking, or changing protective epitopes. Thus, the identification of the protective areas of each toxin provides important data for the construction of multivalent recombinant chimeras. Work involving the use of protective domains of toxins from *C. perfringens* and other pathogens has been performed \[[@B41-toxins-08-00340],[@B43-toxins-08-00340],[@B97-toxins-08-00340]\]. The construction of a chimera composed of CPA-C^(247--370)^, CPB-C^(143--311)^, and ETX^H106P^ may be a viable and promising method of immunoprophylaxis against the animal illness caused by *C. perfringens*.

When the production of veterinary vaccines involves the use of purified antigen, the expression of insoluble proteins involves a laborious and time-consuming production process, since solubilization steps, refolding, and purification are required. Moreover, these processes encumber the manufacturing process, which makes recombinant antigens less commercially competitive than conventional toxoids. An excellent alternative has been demonstrated through the immunization of animals with non-purified recombinant antigens, which consist in the use of cellular fractions (inclusion bodies or supernatant lysate) containing the recombinant antigen, obtained after cell lysis. Lobato et al. \[[@B22-toxins-08-00340]\] used \~200 µg of inclusion bodies of rETX inactivated with formaldehyde directly to vaccinate animals and obtained titers of 40, 14.3, 26, and 13.1 IU/mL of neutralizing antitoxins in rabbits, goats, sheep, and cattle, respectively. Zeng et al. \[[@B26-toxins-08-00340]\] also demonstrated the potential of rCPA inclusion bodies and polyvalent chimeras in the vaccination of mice, cattle, and sows. Inclusion bodies can be easily obtained from cell lysis and semi-purified by centrifuging and washing cycles. In addition, increasing the stability of the antigen, interfering with the action of proteases, and acting as an immunological adjuvant by deposit effect slowly releases the antigen and delays the recognition by the immune system.

The elimination of solubilization and refolding steps, as well as the purification of recombinant antigens, represented a significant advancement. However, a simpler strategy for the production of recombinant vaccines against *C. botulinum* was proposed by Moreira Jr et al. \[[@B27-toxins-08-00340]\]. Vaccines against botulinum toxin serotypes C and D were evaluated in three ways: (1) purified recombinant antigens; (2) recombinant *E. coli* bacterin; and (3) cell lysate fraction (inclusion bodies + supernatant lysis). The purified antigens induced in guinea pigs were 13 and 21 IU/mL of antitoxin C and D respectively. Interestingly, recombinant bacterins and cell lysate factions induced titers of 12 IU/mL of anti-C and 20 IU/mL of anti-D. The use of unpurified recombinant antigens appears as a simple alternative, reducing the time and cost involved in the process by which recombinant veterinary vaccines are produced while also maintaining the quality of the antigens used. Therefore, a recombinant chimera containing protector domains that does not require purification would represent a promising vaccine against *C. perfringens* toxins. A problem pointed out in the literature for production of recombinant antigens in *E. coli* is potential endotoxins (LPS) contamination, which are pyrogenic to humans and animals \[[@B109-toxins-08-00340]\]. However, there were no side-effects reported when unpurified antigens were used in the immunization of guinea pigs \[[@B27-toxins-08-00340]\].

The revaccination of animals vaccinated with conventional toxoid is recommended every six months. Therefore, in addition to the requirement for a simplified production process, the choice of adjuvant for the prolongation of the immune response is extremely important. The use of Al(OH)~3~ as an adjuvant is common in clostridial recombinant vaccines. However, Al(OH)~3~ and saponins induce immune responses that are short in duration; hence, revaccination is recommended two or more times a year \[[@B110-toxins-08-00340]\]. Oil adjuvants induce higher and lasting antibody titers. As such, they are only suitable for use in annual vaccinations, which is desirable for veterinary vaccines \[[@B111-toxins-08-00340],[@B112-toxins-08-00340]\]. Consequently, studies related to the determination of the dynamics of antibodies in animals vaccinated with recombinant antigenic domains, mono- or polyvalent (chimeras or co-administered), associated with different adjuvants, are necessary to determine the immunogenicity of these formulations in production animals.

In terms of antigen dose, the work performed by Chandran et al. \[[@B94-toxins-08-00340]\], evaluated the doses of 50, 100, 200, 300, and 500 μg of rETX in sheep, where doses of 50 and 100 μg generated titers less than 5 IU/mL, and other doses showed no difference in the induction of immune response, generating 7 IU/mL. The subcutaneous was the main route of inoculation in the evaluation of the recombinant toxins; however, some species, such as horses, exhibited exacerbated reactions when vaccinated by this route. The intervals between the first dose and booster ranged from 7 to 35 days between works. The antigen concentration, route of administration, and the dosing interval are factors that also influence the duration of the immune response; therefore, a detailed assessment of the role these factors play in the immunization of each particular specie is of importance.

Some species, such as goats, demonstrate titers of neutralizing antibody of short duration, demanding revaccination every three to four months \[[@B113-toxins-08-00340]\]. Bernáth et al. \[[@B114-toxins-08-00340]\] found that eight weeks between vaccinations is required for toxoid-vaccinated sheep when the Al(OH)~3~ adjuvant is employed. The first dose provides immunity until the administration of the second dose. After that, a second peak in the antibodies is achieved, providing protection for a prolonged period. This work only accompanied the titers during three months \[[@B114-toxins-08-00340]\]. It would be ideal to monitor the dynamics of the antibodies for a year, or during the full period of which the serum antitoxins are detected. These data were obtained from vaccinations with toxoids of *Clostridium* spp., which have well-known problems in inducing titers of neutralizing antibodies due to variability in batches, excessive antigens, and the utilization of formaldehyde to inactivate the toxins. Therefore, the evaluation of all the above factors, such as an adjuvant, administration route, dosing interval, and antigen concentration in different species is essential to facilitate the development and use of veterinary vaccines that contain rCPA, rCPB, and rETX.

6. Conclusions {#sec6-toxins-08-00340}
==============

Recombinant toxins from *C. perfringens* have been efficient on inducing protective immune response in farm animals. Studies over the characteristics of the both CPA and CPB defined that only their *C*-terminal parts can confer protection. Due to structural reasons, this is not true for ETX, to which the development of non-toxic mutants of the whole protein is the main strategy for a vaccine antigen. With these data, it seems that the next step is the construction of a chimeric antigen containing the *C*-terminal parts of CPA and CPB, together with a mutated ETX. Furthermore, the use of fused antigens appears to be interesting for vaccine design, since many published studies are working on this strategy.

Although most of the effective experimental vaccines have been successfully produced in laboratory scale with purified proteins, the same procedure is not attractive for the veterinary vaccine industry. The purification step, for example, increases production expenses and, thus, can impair the use of recombinant antigens in animal vaccines instead of the conventional toxoids. To solve this drawback, the use of SLC, inclusion bodies, or even recombinant bacterins have shown to be a reasonable and low-cost alternative for large-scale production.
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![Representation of the *Clostridium perfringens* Alpha toxin (CPA) structure and the main strategies for its production as a recombinant antigen. The CPA structure (PDB ID: 1CA1, left part) is divided in the *N*-terminal (amino acids 1--246, in green) and *C*-terminal (amino acids 247--370, in red) domains. The most interesting strategies to use CPA as a vaccine antigen consist on using its *C*-terminal domain (CPA-C) fused to the *N*-terminal part of other antigens, such as *C. perfringens* Beta 2 toxin (CPB2) and Beta toxin (CPB), *Staphylococcus aureus* Alpha-hemolysin (SAA; PDB ID: 3ANZ), or *C. perfringens* enterotoxin *C*-terminal domain (CPE-C; PDB ID: 2XH6) (right part).](toxins-08-00340-g001){#toxins-08-00340-f001}

![Representation of the *Clostridium perfringens* Beta toxin (CPB) structure and the main strategies for its production as a recombinant antigen. The CPB structure was predicted by SwissModel online software (Genbank ID: L13198) using standard settings (left part). Since the use of the *C*-terminal domain of CPB (CPB-C) seems to be the most promising option for vaccine development, two predicted B-cell epitopes are shown (magenta), although they have not yet been tested as vaccine. The most interesting strategies to use CPB as a vaccine antigen consist on using its *C*-terminal domain (amino acids 143--311; CPB-C, in red) fused to the *C*-terminal part of other antigens, such as the *C*-terminal domain of *C. perfringens* Iota toxin (CPI-C), or *C. perfringens* Epsilon toxin (ETX; PDB ID: 1UYJ) (right part).](toxins-08-00340-g002){#toxins-08-00340-f002}

![Representation of the *Clostridium perfringens* Epsilon toxin (ETX) structure and the main strategies for its production as a recombinant antigen. The ETX structure (PDB ID: 1UYJ, left part) is divided in three domains, named I, II, and III (cyan, green, and magenta, respectively). Because ETX has two 35-amino acid parallel strands of β-sheets crossing all its structure, passing through domains I, II, and III, the alternative to use ETX as a recombinant vaccine antigen consists on making mutations that reduce its toxicity, such as those in H106, Y196, or F199 (middle part). Moreover, fusing its whole sequence to the *C*-terminal part of other antigens, such as CPB, or expressing it on the cell surface of probiotic bacteria, such as *Lactobacillus casei*, are also interesting strategies (right part).](toxins-08-00340-g003){#toxins-08-00340-f003}

toxins-08-00340-t001_Table 1

###### 

Main diseases caused by *Clostridium perfringens* toxinotypes in production animals.

  Toxinotype   Produced Toxins                                                           Diseases (Affected Animals)
  ------------ ------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------
  A            CPA                                                                       Gas gangrene (all production species) and enterotoxemia (ovine)
  CPA, CPE     Enteritis (equine, caprine, and swine)                                    
  CPA, NetB    Necroticenteritis (poultry)                                               
  CPA, NetF    Neonatal necroticenteritis (foal)                                         
  CPA, CPB2    Necrotic enteritis (piglets), abomasitis (calves), enterocolitis (foal)   
  B            CPA, CPB, ETX                                                             Necrotic enteritis and hemorrhagic enterotoxemia (bovine, ovine, and equine)
  C            CPA, CPB                                                                  Necrotic enteritis and enterotoxemia (bovine, ovine, caprine, swine, and newborn equine); necrotic enteritis (poultry)
  D            CPA, ETX                                                                  Enterotoxemia (ovine, bovine, and caprine)
  E            CPA, CPI                                                                  Hemorrhagic enteritis (lambs, and calves)

Adapted from Revitt-Mill, Rood, and Adans \[[@B4-toxins-08-00340]\] and Li et al. \[[@B11-toxins-08-00340]\].

toxins-08-00340-t002_Table 2

###### 

Immunogenicity of rCPA in model animals.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Molecule                                  Doses                    Via     No. of Doses   Interval (Days)   Adjuvant    Animal Model   Challenge           Survival (%)             References
  ----------------------------------------- ------------------------ ------- -------------- ----------------- ----------- -------------- ------------------- ------------------------ ---------------------------------------------------
  rGST-CPA-C^(247−370)^                     10 µg                    IP      3              14                FIA         Mouse          1 µg of CPA; CAA    100 (6/6)                \[[@B46-toxins-08-00340]\]

  25 µg Cpb                                 83.3 (5/6)                                                                                                                                

  rCPA-N^(1--249)^ ^A^\                     0.36 pM                  IP      2--6           14                FIA         Mouse          50 × MLD CPA        0 (0/6) ^A^              \[[@B44-toxins-08-00340]\]
  rCPA-C^(247--370)^ ^B^\                                                                                                                                                             
  rGST-CPA-C^(247--370)^ ^C^                                                                                                                                                          

  100 (6/6) ^C^                                                                                                                                                                       

  100 (6/6) ^B,C^                                                                                                                                                                     

  10^9^ CFU (10 × LD~100~)                  0 (0/6) ^A^                                                                                                                               

  100 (6/6) ^B,C^                                                                                                                                                                     

  66.6 (4/6) ^C^                                                                                                                                                                      

  rGST-CPA-C                                0.36 pM                  IP      2--6           14                FIA         Mouse          15 µg CPA           100 (6/6)                \[[@B47-toxins-08-00340]\]

  rCPA-C^(251--370)^                        10 µg                    IP      2              14                FCA/FIA     Mouse          1 µg or 10^8^ CFU   100 (10/10)              \[[@B48-toxins-08-00340]\]

  rCPA-C^(281--370)^                        100 (10/10)                                                                                                                               

  rCPA-C^(311--370)^                        60 (6/10)                                                                                                                                 

  rGST-CPA-C^(247--370)^                    10^9^ CFU (75 ng)        IP      3              14                None        Mouse          12 × LD~50~         NE                       \[[@B40-toxins-08-00340]\]

  *B. subtilis*                             5 × 10^10^ (3.6 µg)      PO      21             100 (6/6)                                                                                 

  (Cell surface display)                    2 × 10^9^ (150 ng)       IN      21             100 (6/6)                                                                                 

  rCPAE\                                    30 µg                    SC      4              7--14             FCA/FIA     Mouse          5 × LD~50~ CPA      100 (12/12)              \[[@B43-toxins-08-00340]\]
  (CPA-C^(284--398)^ + CPE-C^(197--312)^)                                                                                                                                             

  5 × LD~50~ CPE                            75 (9/12)                                                                                                                                 

  rCS\                                      50 µg                    SC/IP   3              14                FCA/FIA     Mouse          5 × LD~100~ CPA     100 (6/6)                \[[@B41-toxins-08-00340],[@B42-toxins-08-00340]\]
  (CPA-C^(284--398)^ + SAA^(36--221)^)                                                                                                                                                

  5 × LD~100~ SAA                           100 (6/6)                                                                                                                                 

  5 × LD~100~ CPA + SAA                     83.3 (5/6)                                                                                                                                

  rCPA                                      100 µg                   SC      2              14                Al(OH)~3~   Mouse          1 × LD~100~ ^A^\    80 ^A^, 70 ^B^, 83 ^C^   \[[@B26-toxins-08-00340]\]
                                                                                                                                         2 × LD~100~ ^B^\                             
                                                                                                                                         1 × LD~100~ ^C^                              

  rCPB2B1                                   90 ^A^, 73 ^B^, 93 ^C^                                                                                                                    

  rCPA + CPB2B1                             100 ^A,B,C^                                                                                                                               

  rCPAB2B1                                  93 ^B^, 100 ^A,C^                                                                                                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

rCPA: recombinant *Clostridium perfringen*s Alpha toxin; rCPA-N: recombinant *C. perfringen*s Alpha toxin *N*-terminal domain; rCPA-C: recombinant *C. perfringen*s Alpha toxin *C*-terminal domain; rGST-CPA-C: recombinant *C. perfringen*s Alpha toxin *C*-terminal domain fused with Glutathion S-transferase (GST); CPE: *C. perfringens* Enterotoxin; SAA: *Staphylococcus aureus* Alpha-hemolysin; rCPB2B1: recombinant *C. perfringens* Beta and Beta 2 toxins fused; rCPAB2B1: recombinant *C. perfringens* Alpha, Beta and Beta 2 toxins fused; IP: intraperitoneal; PO: oral administration (*per os*); IN: Intranasal; SC: Subcutaneous; FCA: Freund's complete adjuvant; FIA: Freund's incomplete adjuvant; CAA: *Clostridium absonum* Alpha toxin; Cpb: *Clostridium bifermentans* phospholipase C; MLD: Mouse lethal dose; CFU: Colony-forming unit; NE: Not evaluated; ^A,B,C^ The indicated survival percentage corresponds to either the antigens in the first column, or the challenge, which are marked with the same letter.

toxins-08-00340-t003_Table 3

###### 

Immunogenicity of rCPB in model animals.

  Molecule                                  Doses             Via           No. of Doses   Interval (Days)   Adjuvant    Animal Model   Challenge         Protection (IU/mL) or Survival (%)   References
  ----------------------------------------- ----------------- ------------- -------------- ----------------- ----------- -------------- ----------------- ------------------------------------ ----------------------------
  rCPB                                      100 µg            SC            2              21                Al(OH)~3~   Rabbit         \-                10 IU/mL                             \[[@B67-toxins-08-00340]\]
  rETXCPB (ETX ^A^ + CPB ^B^)               0.5 mL            IP            2              21                None        Rabbit         \-                6 ^A^ and 10 ^B^ IU/mL               \[[@B71-toxins-08-00340]\]
  rCPA                                      200 µg            SC            2              21                Al(OH)~3~   Rabbit         \-                9.6 IU/mL                            \[[@B68-toxins-08-00340]\]
  rCPB                                      20.4 IU/mL                                                                                                                                         
  rCPIB                                     30 µg             SC            3              14                FCA/FIA     Mouse          5 × LD~100~ CPB   83% (10/12)                          \[[@B70-toxins-08-00340]\]
  (CPI-C^(466--665)^ + CPB-C^(143--311)^)   5 × LD~100~ CPI   91% (11/12)                                                                                                                      

CPB: *Clostridium perfringens* Beta toxin; ETX: *C. perfringens* Epsilon toxin; CPI: *C. perfringens* Iota toxin; rCPB: recombinant *C. perfringens* Beta toxin; rCPA: recombinant *C. perfringens* Alpha toxin; CPI-C: *C. perfringens* Iota toxin *C*-terminal domain; CPB-C: *C. perfringens* Beta toxin *C*-terminal domain; SC: Subcutaneous; IP: Intraperitoneal; FCA: Freund's complete adjuvant; FIA: Freund's incomplete adjuvant. ^A,B^ The indicated survival percentage corresponds to the antigens in the first column marked with the same letter.

toxins-08-00340-t004_Table 4

###### 

Immunogenicity of rETX in model animals.

  Molecule                      Doses                       Via                                          No. of Doses   Interval (Days)   Adjuvant    Animal Model   Challenge               Survival (%) or Protection (IU/mL)   References
  ----------------------------- --------------------------- -------------------------------------------- -------------- ----------------- ----------- -------------- ----------------------- ------------------------------------ ----------------------------
  rETX                          50; 100; 200; 300; 500 µg   SC                                           2              21                Al(OH)~3~   Rabbit         \-                      3; 5; 7; 7; 8; 7 IU/mL               \[[@B94-toxins-08-00340]\]
  rETX                          50; 100; 200 µg             SC                                           5              2--10             FCA/FIA     Rabbit         \-                      10; 30; 40 IU/mL                     \[[@B98-toxins-08-00340]\]
  rCPA, rCPB, rETX              200 µg                      SC                                           2              21                Al(OH)~3~   Rabbit         \-                      9.6; 24.4; 25 IU/mL                  \[[@B69-toxins-08-00340]\]
  rETX^H106P^                   0.27 nmol                   IP                                           3              14--21            FIA         Mouse          100 and 1000 × LD~50~   100% (30/30)                         \[[@B80-toxins-08-00340]\]
  rETX^H106P^                   10 µg                       SC                                           3              17--21            Al(OH)~3~   Mouse          100 × LD~50~            100% (3/3)                           \[[@B95-toxins-08-00340]\]
  rETX^F199E^                                                                                                                                                                                                                     
  rETX^Y196E^-C                 5 µg ^A^                    SC IP                                        3              14                FCA         Mouse          100 × LD~50~ ^a^        100% (5/5) ^Aab,Bab,Cab^             \[[@B96-toxins-08-00340]\]
  10 µg ^B^                     500 × LD~50~ ^b^            20 ^Cb^; 80 ^Aa^; 100% ^Ba,Ca^ (1; 4; 5/5)                                                                                                                            
  15 µg ^C^                     1000 × LD~50~ ^c^           80% (4/5) ^Ca^                                                                                                                                                        
  *Lactobacillus casei*         10^9^ CFU                   IG                                           3              16--21            None        Mouse          200 × LD~50~            100% (10/10)                         \[[@B97-toxins-08-00340]\]
  (Cell surface display)                                                                                                                                                                                                          
  rETX^H106P^                                                                                                                                                                                                                     
  rETXCPB (ETX ^A^ + CPB ^B^)   0.5 mL                      IP                                           2              21                None        Rabbit         \-                      6 ^A^ and 10 ^B^ IU/mL               \[[@B71-toxins-08-00340]\]

CPB: *Clostridium perfringens* Beta toxin; ETX: *C. perfringens* Epsilon toxin; rCPA: recombinant *C. perfringen*s Alpha toxin; rETX: recombinant *C. perfringens* Epsilon toxin; rCPA: recombinant *C. perfringens* Alpha toxin; rCPB: recombinant *C. perfringens* Beta toxin; rETX^H106P^: recombinant *C. perfringens* Epsilon toxin with mutation in H106 amino acid; rETX^F199E^: recombinant *C. perfringens* Epsilon toxin with mutation in F199 amino acid; rETX^Y196E^-C: recombinant *C. perfringens* Epsilon toxin with mutation in Y196 amino acid and containing *C*-terminal domain; CFU: Colony-forming unit; SC: Subcutaneous; IP: Intraperitoneal; IG: Intragastric; FCA: Freund's complete adjuvant; FIA: Freund's incomplete adjuvant. ^a,b,c,A,B,C^ The indicated survival percentage corresponds to either the antigens in the first column, or the challenge, which are marked with the same letter.

toxins-08-00340-t005_Table 5

###### 

Immune response against CPA, CPB, and ETX generated by recombinant antigens in farm animals.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antigens           Doses (via)                          Boost Dose (Day)   Adjuvant        Animal                Method   Protection (UI/mL)   References                                                                
  ------------------ ------------------------------------ ------------------ --------------- --------------------- -------- -------------------- ---------------------------- -------------- ----------------------------- ----------------------------
  rETX               50, 100, 200, 300, and 500 μg (SC)   35                 Al(OH)~3~       Sheep                 SN       2; 5; 7; 7; 9; 9     \[[@B94-toxins-08-00340]\]                                                

  rETX               200 μg (SC)                          14                 Al(OH)~3~       Cattle                SN       13.1                 \[[@B22-toxins-08-00340]\]                                                

  Sheep              26                                                                                                                                                                                                    

  Goat               14.3                                                                                                                                                                                                  

  rCPA\              200 μg (SC)                          14                 Al(OH)~3~ gel   **Animal/specimen**   SN       **rCPA**             **rCPB2B1**                  **rCPAB2B1**   **rCPA + rCB2B1**             \[[@B26-toxins-08-00340]\]
  rCPB2B1\                                                                                                                                                                                                                 
  rCPA+rCPB2B2\                                                                                                                                                                                                            
  rCPAB2B1                                                                                                                                                                                                                 

  Cattle/Serum       1                                    2                  2               3                                                                                                                             

  Cattle/Colostrum   0                                    1                  1               1                                                                                                                             

  Swine/Serum        4                                    6                  6               6                                                                                                                             

  Swine/Colostrum    1                                    2                  2               8                                                                                                                             

  rCPA, rCPB, rETX   300 μg (SC)                          14                 ISA 15A VG      Calves                ELISA    **CPA**              **CPB**                      **ETX**        \[[@B105-toxins-08-00340]\]   

  23.04              33.7                                 9.43                                                                                                                                                             

  rCPA, rCPB         200 μg (SC)                          35                 Al(OH)~3~       Swine                 SN       6                    14.5                         \-             \[[@B68-toxins-08-00340]\]    

  Piglets            4.2                                  10.9               \-                                                                                                                                            

  rCPA, rCPB, rETX   200 μg (SC)                          35                 Al(OH)~3~       Cattle                SN       5.19                 13.71                        12.74          \[[@B69-toxins-08-00340]\]    

  Sheep              4.34                                 13.71              7.66                                                                                                                                          

  Goat               4.7                                  13.71              8.91                                                                                                                                          
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CPA: *Clostridium perfringens* Alpha toxin; CPB: *C. perfringens* Beta toxin; ETX: *C. perfringens* Epsilon toxin; rCPA: recombinant *C. perfringen*s Alpha toxin; rCPB: recombinant *C. perfringens* Beta toxin; rETX: recombinant *C. perfringens* Epsilon toxin; rCPB2B1: recombinant *C. perfringens* Beta and Beta 2 toxins fused; rCPAB2B1: recombinant *C. perfringens* Alpha, Beta and Beta 2 toxins fused; SC: Subcutaneous; SN: Serum neutralization assay.

[^1]: Current address: Abteilung Biotechnologie, Institut für Biochemie, Biotechnologie und Bioinformatik, Technische Universität Braunschweig, Spielmannstr. 7, Braunschweig 38106, Germany.

[^2]: Current address: School of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey GU2 7XH, UK.
